Multidisciplinary Management of Advanced laryngeal cancer
-
Upload
rajesh-balakrishnan -
Category
Health & Medicine
-
view
294 -
download
0
Transcript of Multidisciplinary Management of Advanced laryngeal cancer
![Page 1: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/1.jpg)
Locally Advanced Vocal Cord Tumors- Evidence Based Approach
Dr. Rajesh Balakrishnan
Associate Professor
Christian Medical College, Vellore
![Page 2: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/2.jpg)
LEARNING OBJECTIVES
Staging and Grouping
Current treatment protocols
Evidence – Clinical trials
Radiotherapy Volume delineation Guidelines
What to do after CRT / ICT
![Page 3: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/3.jpg)
MILESTONES IN LARYNX/HYPOPHARYNX MANAGEMENT
1st TL
1st PLs
1st RT Laser CO2
SCPL
Trial VA
Trial EORTC
Trial RTOG
Trial EORTC
Trial GORTEC
SURGERY RADIOTHERAPY LASER
CT MRI
ASCO1982
1873 1878 1903 1970s 1994 1996 2003 2005 2007
Courtesy Dr. J-L Lefebvre
ORGAN PRESERVATION PROTOCOLS
![Page 4: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/4.jpg)
TIME TREND ANALYSIS - LARYNX
FIVE- YEAR RELATIVE SUVIVAL RATE
![Page 5: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/5.jpg)
STAGING AND GROUPING
![Page 6: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/6.jpg)
ANATOMY
![Page 7: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/7.jpg)
Ref: Book - Target Volume Delineation
and Field Setup
ANATOMY
![Page 8: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/8.jpg)
STAGE GROUPING
T1< 2cm
T22-4 cm
T3>4cm
T4a+
Invasion
T4b++Invasio
n
M1
N0 I II III IV A IV B IV C
N1<3cmSIPSI
III III III IV A IV B IV C
N23-6cm
BILIV A IV A IV A IV A IV B IV C
N3>6cm IV B IV B IV B IV B IV B IV C
![Page 9: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/9.jpg)
CLASSIFICATION – LARYNGEALTUMORS
T1< 2cm
T22-4 cm
T3>4cm
T4a+
Invasion
T4b++Invasio
nM1
N0 EARLY LOCALLY ADVANCED
META
STATIC
N1<3cmSIPSI
LOCALLY ADVANCED
N23-6cm
BIL
N3>6cm
Very Locally Advancedo T4bo Unresectable No Unfit for surgery
![Page 10: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/10.jpg)
TREATMENT MODALITIES IN LARYNX TUMORS 2014
Surgery
Radiotherapy (RT)
Chemotherapy (CT)Combined therapy
Palliative therapy
Targeted TherapyAlone or in combination with CMT, RT, CT
} As a single modality
1. Induction Chemotherapy(ICT)2. Concomitant CT and RT3. Sequential therapy (ICT > CCRT)4. Adjuvant CT (ART) 5. Postoperative (RT /CCCRT)
![Page 11: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/11.jpg)
TREATMENT OPTIONS
T1< 2cm
T22-4 cm
T3>4cm
T4a+ Invasion
T4b++Invasion
M1
N0I- II
EARLYRESECTABLE
III -IV B LOCALLY ADVANCED
META
STATIC
CH
EMO
THER
AP
Y
III??RESECTABLE
IV A??
IV BIRRESECTABLE
N1<3cmSIPSI
IIILOCALLY
ADVANCEDRESECTABLE
III??RESECTABLE
IV A??
IV BIRRESECTABLE
N23-6cm
BIL
IV ALOCALLY ADVANCED
?? RESECTABLE
N3>6cm
IV BLOCALLY ADVANCED
?? IRRESECTABLE
![Page 12: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/12.jpg)
TREATMENT OPTIONST1
< 2cmT2
2-4 cmT3
>4cmT4a
+ InvasionT4b
++InvasionM1
N0 EARLYRESECTABLE
S = RT
LOCALLY ADVANCED
IV CMETCT
??RESECTABLECRT
??CRT
IRRESECTABLECRT
N1<3cmSIPSI
LOCALLY ADVANCEDRESECTABLES > RT / CRT
??RESECTABLECRT
??CRT
IRRESECTABLECRT
N23-6cm
BIL
LOCALLY ADVANCED?? RESECTABLE
CRT
N3>6cm
LOCALLY ADVANCED?? IRRESECTABLE
CRT
![Page 13: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/13.jpg)
T1< 2cm
T22-4 cm
T3>4cm
T4a+ Invasion
T4b++Invasion
M1
N0 LOCALLY ADVANCED
IV CMETCT
??RESECTABLE
S > RTS > CRT CRT > S
??CRT > s
IRRESECTABLECRT
N1<3cmSIPSI
LOCALLY ADVANCEDRESECTABLES > RT /CRT
N23-6cm
BIL
LOCALLY ADVANCED?? RESECTABLE
CRT > S
N3>6cm
LOCALLY ADVANCED?? IRRESECTABLE
CRT
![Page 14: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/14.jpg)
Treatment of locally advanced Laryngeal Tumors
Stage III-IVB: T3-4ab, N1-3
Resectable --T3 N1
Surgery RT
CRT
Borderline -- T4a , N2 Treat as Irresectable
Irresectable-- T4b , N3
CCRT / BRT Surg
ICT Surg or RT/CRT
ICT Surg RT/CRT
ICT RT/CRT ? Surg
![Page 15: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/15.jpg)
HOW TO CHOOSE THE TREATMENT DECISION ?
![Page 16: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/16.jpg)
Patient Factor
• Pretreatment condition
• Chronic diseases, malnutirtion, poor oral health
• Patient priorities
• Cure, live long , Pain free, Disability free
Disease Factor
• TNM Stage
• Early / LA / Metastatic
• Emerging prognostic biomarkers
• EGFR / p16 / HPV
• Specific Risk factors for LR /DM
Treatment Factor
• Morbidity of treatment offered
• Surgery
• RT + Chemo
• Targeted agents
HOW TO MAKE ATREATMENT DECISION?
![Page 17: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/17.jpg)
PATIENT PRIORITIES
![Page 18: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/18.jpg)
Treatment decision making flow charts
https://tmc.gov.in/clinicalguidelines/EBM/Vol11/TreatmentofAlgorithms.pdfhttps://tmc.gov.in/clinicalguidelines/EBM/Vol11/HeadandNeck.pdf
![Page 19: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/19.jpg)
Larynx – T1-2 N2-3Normal Cord mobility
Larynx T1-2,
N2-3
Non Surgical Options
Normal Cr Cl CRT
Cr Cl – poor
Poor PS
Concurrent Targeted therapy
with RT
Surgical
Options
Trans oral Laser microsurgery + BLND+RT /CRT
Open Partial Laryngectomy + BLND + RT/CRT
Split
therapy
Neck Dissection with Adjuvant therapy (RT/CRT)
![Page 20: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/20.jpg)
Larynx T3 Any N , Operable nodes
Larynx T3 , Any N (Operable
nodes)
Laryngeal Function Intact
Normal Cr CL CRT
Poor Cr Cl
Concurrent Targeted therapy with RT
Altered Fraction RT for N0-1
Open PL + Ipsi ND (N0) and BLND (N+) with Adjvuant RT /CRT
Laryngeal function
Compromised NTL / TL with BLND + Adjuvant RT/CRT
![Page 21: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/21.jpg)
Laryngeal Function
and Framework
Function Intact
Cartilage - N
Cr ClNormal
CRT
NTL /TL + BLND
+ RT/CRT
Cr ClCompromised
Concurrent Targeted Therapy
Altered Fraction RT
NTL/TL with BLND + RT/CRT
Function Compromised
Cartilage damaged
NTL/TL with BLND + RT/CRT
Larynx T4 Any N
![Page 22: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/22.jpg)
• CRT or ICT RT/CRT
• ± Surgery to T and N if feasablePS 0-1• RT or CRT
• ± Surgery to T and N if feasablePS 2• Palliative RT
• Single agent Chemotherapy
• Reassess for Surgery if feasablePS 3
• Best Supportive CarePS 4
Very locally-advanced HNCInclude T4b, unresectable N, unfit for surgery
![Page 23: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/23.jpg)
CCRT VS ICT /Sequential therapy
![Page 24: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/24.jpg)
PARADIGM TRIAL
SPANISH TRIAL
![Page 25: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/25.jpg)
![Page 26: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/26.jpg)
![Page 27: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/27.jpg)
![Page 28: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/28.jpg)
![Page 29: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/29.jpg)
ORGAN PRESERVATION TRIALS
![Page 30: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/30.jpg)
![Page 31: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/31.jpg)
![Page 32: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/32.jpg)
RTOG 91-11: LFS and OS
![Page 33: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/33.jpg)
![Page 34: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/34.jpg)
![Page 35: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/35.jpg)
3 YRS DATA
![Page 36: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/36.jpg)
5 YRS DATA
![Page 37: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/37.jpg)
Organ Preservation – Larynx cancer
• Compared with RT alone, LFS significantly better with
– ICT followed by RT
– RT/concurrent cisplatin
• Compared with ICT followed by RT or RT alone
– Laryngeal Preservation and locoregional control significantly better with RT/concurrent cisplatin
• No significant difference in OS
• CRT now the standard of care in organ preservation
![Page 38: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/38.jpg)
MACH-NC
• 2000:
– 63 trial (10 741 patients) between 1965-1993
– oropharynx, oral cavity, larynx, or hypopharynx
• 2007 update:
– 63 +24 trials (87 trials) (16 665 patients) between 1965 -2000
– oropharynx, oral cavity, larynx, or hypopharynx, Npx
• 2009 update
• 2011:
– Site analysis
![Page 39: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/39.jpg)
MACH-HN Meta-Analysis
Pignon et al. Lancet, 2000
![Page 40: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/40.jpg)
MACH- NC 2009 Update
Radiotherapy and Oncology 92 (2009) 4–14
![Page 41: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/41.jpg)
MACH- NC 2009 UpdateCCRRT vs Induction (Indirect comparisons)
![Page 42: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/42.jpg)
MACH- NC 2011 UpdateHN Subsites
![Page 43: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/43.jpg)
MACH- NC 2011 UpdateHN Subsites
![Page 44: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/44.jpg)
Pignon et al, Radiother Oncol 2009; Blanchard Radiother Oncol 2011)
MACH –HN Recent Data
![Page 45: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/45.jpg)
![Page 46: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/46.jpg)
ICT IN LRA-SCCHN IN 2014 CONCLUSIONS
![Page 47: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/47.jpg)
BIORADIOTHERAPY
![Page 48: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/48.jpg)
![Page 49: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/49.jpg)
![Page 50: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/50.jpg)
RTOG 0522Does Adding Cetuximab to RT improve Outcome
![Page 51: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/51.jpg)
RTOG 0522 – Larynx subsiteDoes Adding Cetuximab to RT improve Outcome
![Page 52: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/52.jpg)
RTOG 0522 Does Adding Cetuximab to RT improve Outcome
![Page 53: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/53.jpg)
5 Trials – Total of 1808 patientsConclusions: Platinum-based CTRT still remains the standard of care in LAHNC until prospective trials can demonstrate equivalence.
J Clin Oncol 32:5s, 2014 (suppl; abstr 6014)
Concomitant RT PLUS Cisplatin vs CetuximabA meta-analysis
![Page 54: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/54.jpg)
RADIOTHERAPY FOR LARYNGEAL TUMORS
![Page 55: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/55.jpg)
EVIDENCE FOR NEED FOR POST OP RT
![Page 56: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/56.jpg)
EORTC 22931 / RTOG 9501
![Page 57: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/57.jpg)
Bernier, Cooper. Head Neck 2005;27:843
Combined EORTC /RTOG Analysis
![Page 58: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/58.jpg)
Overall Survival Status
![Page 59: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/59.jpg)
Combined EORTC /RTOG Analysis
Bernier, Cooper. Head Neck 2005;27:843
Overall Survival for Patients WITHOUT Positive Margin and/or ECE
![Page 60: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/60.jpg)
Bernier, Cooper. Head Neck 2005;27:843
Combined EORTC /RTOG Analysis
Overall Survival for Patients WITH Positive Margin and/or ECE
5 yr Follow up Data
![Page 61: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/61.jpg)
Long term followup of RTOG 9501Patients with Positive Margin and/or ECE
Cooper et al. IJROBP 201210 yr Follow up Data
![Page 62: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/62.jpg)
Postoperative RT- Indications
1. Positive resection margins
2. Extracapsular lymph node
spread
Any 2 of the following
3. Close margins < 5 mm.
4. Invasion of soft tissues. (T3/T4)
5. Two or more lymph nodes positive.
6. More than one positive nodal group.
7. Involved node > 3 cm in diameter.
8. Multicentre primary.
9. Perineural invasion.
10. Lymphovascular Invasion
OR
1 or 2 --- Post op ChemoRT Any 2 of 3-10 ---- Post op RT only
![Page 63: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/63.jpg)
Other factors to be considered
11. Poor differentiation
12. Stage T3/4
13. Oral cancer with Level 4/5 positive node
14. CIS, dysplasia at edge of resection margin
15. Uncertainties concerning surgical/pathological findings
16. HPV negativity
![Page 64: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/64.jpg)
RADIOTHERAPY TECHNIQUES AND VOLUME DELINEATION
![Page 65: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/65.jpg)
Target Volume Delineation (1)
• If neoadjuvant chemotherapy has been givenprior to radiation, the targets should beoutlined on the planning CT according totheir prechemotherapy extent.
• Review the operation notes and discuss withsurgeon to know more about areas ofconcern.
• Review the detailed HPE report and ifnecessary discuss with the pathologist
![Page 66: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/66.jpg)
Target Volume Delineation (2)
• May deliver RT as soon as the wound ishealed
• Ideally initiate after 2 weeks but within 6weeks after surgery
• Registration of Pre-Op images to sim CT
• Use proper immobilisation device and to doPlanning CT with Contrast and atleast 3 mmslice thickness
• PET – CT for fusion where ever possible
![Page 67: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/67.jpg)
Post operative RT Dose
• 60 Gy in 30 fractionsNegative Margins
• 66 Gy in 33 fractionsMicroscopically positive
margins
• 70 Gy in 35 fractionsGross Residual Disease
• Stoma Boost – With Electrons 10 Gy in 5 fractions (Level II Evidence)
Subglottic Extension
• If positive Margin or ECE present.Chemotherapy
Text book: Practical Essentials of IMRT –Chao, 3rd Edition
![Page 68: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/68.jpg)
Nodal Volume Delineation - Larynx
• N2c Cases when Level 2 is involvedSubmandibular nodes
• Ipsilateral Neck in all casesUpper Deep jugular nodes
(Junctional / Parapharyngeal)
• Bilaterally all cases (Level 2-4)Jugulodigastric, mid jugular,
SCLN
• All cases - Ipsilateral if jugular nodes are involvedPosterior Cervical nodes (Level
5)
• If evidence of metastases is presentRetropharyngeal nodes
Text book: Practical Essentials of IMRT –Chao, 3rd Edition
![Page 69: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/69.jpg)
Postoperative IMRT
• Residual Tumor and adjacent region
• Surgical bed with soft tissue invasion
• Extracapsular extension of nodesCTV1
• Prophylactically the treated neck CTV2
Text book: Practical Essentials of IMRT –Chao, 3rd Edition
![Page 70: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/70.jpg)
Post op IMRT
T2 N2b MoCA SupraglottisClinically Level 2 node +
TL + BLND
HPE- Sq cell carcinoma4 nodes positiveNo ECE
CTV 1 – Surgical BedCTV 2 – Prophylactic neck
![Page 71: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/71.jpg)
Post op IMRT for Laryngeal Cancer
![Page 72: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/72.jpg)
Definitive IMRT
• Gross Tumor (Primary and Nodes) and the region adjacent to itCTV1
• High risk regions in the Ipsilateral neckCTV2
• Prophylactically treated neckCTV 3Text book: Practical Essentials of IMRT –Chao, 3rd Edition
![Page 73: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/73.jpg)
Radical IMRT
T3 N2b Mo , Ca Supraglottis
Presentation - Hoarseness and sore throat.
DL Scopy – A Tumor in the left false vocal cord and AEF. Multiple left-sided lymph nodes
GTV pGTV n CTV 1 GTVp+n + 5mmCTV 2 IN(Adjacent LN)CTV 3 IN + CN + RPLN
![Page 74: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/74.jpg)
Radical IMRT
T3 N2b Mo , Ca Supraglottis
Presentation - Hoarseness and sore throat. DL Scopy – A Tumor in the left false vocal cord and AEF. Multiple left-sided lymph nodes
GTV pGTV nCTV 1 GTVp+n + 5mmCTV 2 IN(Adjacent LN)CTV 3 IN + CN + RPLN
![Page 75: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/75.jpg)
CTV Guidelines – Definitive IMRT Larynx
Tumor Site Stage CTV 1 CTV 2 CTV3
Glottis
T1-2 N0 GTVp +5mm ----- -----
T3-4 N0 GTVp+5mmWhole laryngeal apparatus
IN + CN (II-V)
Any T , N+GTVp+n+ 5mm
IN(Adjacent LN) + Whole Laryngeal Apparatus
IN + CN + RPLN*
Supraglottis
Any T , N0 GTVp+5mmWhole laryngeal apparatus
IN + CN (II-V)
Any T , N+GTVp+n+5mm
IN(Adjacent LN)+Whole laryngeal apparatus
IN + CN + RPLN*
Text book: Practical Essentials of IMRT –Chao, 3rd Edition
Adjacent LN – with in 3 cm of CTV 1RPLN * --- Include when midline tumors/ advanced tumors
![Page 76: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/76.jpg)
Dose Prescription – Definitive IMRT Larynx
Dose for ChemoRT
CTV 1 CTV 2 CTV3
33 fractions 70 Gy in 33 # 59.4 Gy in 33 # 54 Gy in 33 #
35 fractions 70 Gy in 35 # 63 Gy in 35 # 56 Gy in 35 #
Text book: Practical Essentials of IMRT –Chao, 3rd Edition
![Page 77: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/77.jpg)
Post Organ Preservation Treatment Evaluation
• DL Scopy / NPL scopy and CT scan 6 weeks after
treatment
• PETCT scan if ordered to be done only after 12weeks
• Thyroid Function tests after 6 months orsymptomatic whichever is earlier
• Swallowing Therapy To initiate in pre treatmentsetting and continue during and after radiation
![Page 78: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/78.jpg)
Treatments following CRT in LA Larynx Tumors
CR (T + N)
Follow up
Residual
(PR /SD)
Resectable
• R0 in T and N – Follow up
• R1 /R2 – Chemotherapy
Unresectable
• Treat as PD
• Chemotherapy
Metastases Progression
Palliative Chemotherapy
![Page 79: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/79.jpg)
Time Line for Salvage Surgery after CRT
ee
Salvage surgery within 4-6 months after CRT
![Page 80: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/80.jpg)
• Radical RT onlyCR – Both T and
N
• RT and then assess for node
• If residual post RT – Neck dissectionCR – T only
• RT /CCRT and follow up
• If Residual post RT – Salvage SurgeryPR – T only
• Surgery Post op RT /CRTSD or PD at T
Treatments after ICT Induction therapy
![Page 81: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/81.jpg)
• Chemo radiotherapy (concomitant or sequential) isbetter than RT alone in irresectable HN cancer andresectable glottic or supraglottic malignancies
• CCRT is better than SCRT in laryngeal preservation
• SCRT is not significantly inferior to CCRT inirresectable tumors
Conclusion
![Page 82: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/82.jpg)
THANK YOU
![Page 83: Multidisciplinary Management of Advanced laryngeal cancer](https://reader033.fdocuments.us/reader033/viewer/2022050922/55a205321a28abe9648b4611/html5/thumbnails/83.jpg)
Increase the Likelihood of Successful Larynx Preservation (cont’d)
• Factors Associated with Decreased Larynx-Preservation Outcomes:
– Male / Smoker
– Anemia (at start of treatment)
– Advanced T stage
– Clinically detectable impaired vocal cord mobility
– Subglottic extension
– Involvement of anterior commissure
– Large tumor volume
– Invasion of specific anatomic sites (determined by CT or MRI)